Detection of antibodies against SARS-CoV‑2
Development of an automated flow-based chemiluminescence microarray immunoassay (CL-MIA) for the detection of antibodies against SARS-CoV‑2 RBD/spike protein and N protein in human serum and plasma in less than 8 min with high specificity and sensitivity.
In the face of the COVID-19 pandemic, the need for rapid serological tests that allow multiplexing emerged, as antibody seropositivity can instruct about individual immunity after an infection with SARS-CoV‑2 or after vaccination. As many commercially available antibody tests are either time-consuming or tend to produce false negative or false positive results when only one antigen is considered, we developed an automated, flow-based chemiluminescence microarray immunoassay (CL-MIA) that allows for the detection of antibodies to SARS-CoV‑2 RBD/spike protein and N protein in human serum and plasma in less than 8 min. The CoVRapid CL-MIA was tested with SARS-CoV‑2 serology positive or negative samples, resulting in 100% diagnostic specificity and 100% diagnostic sensitivity, thus outcompeting other commercial tests run on the same sample set.
Automated, flow-based chemiluminescence microarray immunoassay for the rapid multiplex detection of IgG antibodies to SARS-CoV‑2 in human serum and plasma (CoVRapid CL-MIA)
Julia Klüpfel & Rosa Carolina Koros & Kerstin Dehne & Martin Ungerer & Silvia Würstle & Josef Mautner & Martin Feuerherd & Ulrike Protzer & Oliver Hayden & Martin Elsner & Michael Seidel